After two years of recalibration, life sciences venture capital roared back in 2025 with $38.4 billion deployed across more than 2,900 deals globally. This annual landscape report from Legacy Venture Capital examines every sector, stage, and signal that defined the year—and maps what it means for founders and investors entering 2026.
The life sciences venture ecosystem entered 2025 in a cautious posture. The post-pandemic correction that began in late 2022 had compressed valuations, lengthened fundraising timelines, and forced a renewed emphasis on capital efficiency. Yet by the close of the year, the data tell a different story: total venture investment in life sciences reached $38.4 billion globally, up 22% from the $31.5 billion recorded in 2024 and marking the strongest recovery year since the 2021 peak of $46.2 billion. Deal volume rose modestly to 2,920 transactions, a 9% increase over 2024's 2,680 deals, signaling that the recovery was driven more by larger round sizes than by a flood of new company formations.
Several macro forces converged to produce this recovery. The Federal Reserve's decision to hold rates steady through much of 2025 provided institutional allocators with enough predictability to re-enter venture commitments. The Inflation Reduction Act's drug pricing provisions, initially a headwind for pharma sentiment in 2023, matured into a tailwind as companies pivoted toward high-value therapeutic niches and rare diseases where pricing flexibility remains intact. Meanwhile, the explosive progress in AI-enabled drug discovery created an entirely new category of capital demand, attracting both traditional healthcare VCs and crossover technology investors.
Therapeutics—encompassing both traditional pharmaceuticals and next-generation biotechnology—remained the dominant sector, capturing $18.7 billion or 48.7% of total life sciences venture investment in 2025. Within therapeutics, oncology continued to command the largest share at $6.1 billion across 410 deals, followed by immunology and inflammation ($3.8B), neuroscience ($2.9B), and rare and genetic diseases ($2.4B). Cell and gene therapy investments stabilized at $3.5 billion after the correction from their 2021 highs, with investors favoring companies that had addressed manufacturing scalability and demonstrated durable clinical responses.
Medical devices and medtech drew $7.2 billion in venture funding, a 28% increase year-over-year and the sector's strongest year since 2019. The growth was propelled by surgical robotics, AI-augmented imaging systems, and a resurgence in minimally invasive cardiovascular devices. Notably, several pre-revenue robotic surgery startups raised Series B rounds exceeding $100 million, reflecting investor conviction that the $14 billion global surgical robotics market is still in its early innings.
Digital health venture capital totaled $5.8 billion across 680 deals, a modest 6% decline from 2024. The sector continued its post-pandemic normalization, with investors increasingly separating “digital health” companies with genuine clinical evidence and reimbursement pathways from software-only wellness products. Companies demonstrating measurable clinical outcomes and payer partnerships commanded premium valuations, while direct-to-consumer models faced tighter scrutiny. The average Series A in digital health fell to $12.8 million from $14.3 million in 2024, though the best-positioned companies still raised outsized rounds.
Diagnostics experienced a meaningful renaissance, with $3.4 billion invested across 320 deals. Liquid biopsy companies led the charge, buoyed by expanding Medicare coverage decisions for multi-cancer early detection tests and growing real-world evidence supporting their clinical utility. Point-of-care diagnostics also attracted significant capital, particularly platforms combining multiplex detection with at-home collection capabilities.
“The 2025 landscape rewarded specificity. Investors didn't just return to life sciences—they returned with sharper theses, deeper diligence, and a clear bias toward companies with differentiated biology or validated platform advantages.”
One of the defining stories of 2025 was the return of conviction to early-stage life sciences investing. Pre-seed and seed deals accounted for $3.1 billion in aggregate investment across 840 transactions, up 31% from 2024. The median pre-seed round reached $2.4 million, while the median seed round climbed to $5.8 million—both record highs for the sector. This expansion was driven by several factors: the maturation of AI-first biotech platforms lowering the cost of early validation, a new generation of scientist-founders exiting industry roles, and the emergence of specialized early-stage vehicles (including funds like Legacy Venture Capital) purpose-built for the unique risk profile of pre-seed and seed life sciences.
Series A rounds totaled $9.6 billion across 620 deals, with a median round size of $18.5 million. The Series A bar remained high: the median company raising a Series A in 2025 had 14 months of preclinical data and at least one patent filing, compared to just 9 months and no IP filings at the height of the 2021 market. Series B investment reached $12.4 billion, heavily concentrated in clinical-stage companies with Phase I data readouts. Series C and later rounds accounted for $13.3 billion, dominated by a handful of mega-rounds exceeding $200 million from companies approaching pivotal trials or regulatory submissions.
If 2024 was the year of AI-in-bio hype, 2025 was the year of AI-in-bio proof. Companies deploying artificial intelligence and machine learning across the drug discovery pipeline attracted $6.3 billion in venture funding, representing 16.4% of all life sciences VC—up from 11.2% in 2024 and just 4.8% in 2022. But the composition of this category shifted dramatically. Investors moved away from “AI platform” companies with broad, undifferentiated discovery offerings and toward companies applying AI to specific, high-value bottlenecks: target identification using foundation models trained on multi-omic datasets, generative chemistry for novel molecular scaffolds, and predictive toxicology models reducing late-stage attrition.
The most significant validation came from clinical pipelines. In 2025, 18 AI-discovered or AI-optimized drug candidates entered Phase I clinical trials, up from 11 in 2024. Three AI-derived compounds advanced to Phase II, and two received Breakthrough Therapy Designation from the FDA. Perhaps most strikingly, the average time from target nomination to IND filing for AI-native programs fell to 28 months, compared to an industry-wide average of 54 months for traditional approaches—a compression of the discovery timeline that, if sustained, could fundamentally alter the venture capital return model for early-stage therapeutics.
“AI is no longer a differentiator in life sciences—it is table stakes. The question has shifted from ‘do you use AI?’ to ‘what proprietary data do you train it on, and how does that translate to clinical probability of success?’”
Foundation models for biology emerged as a particular area of investor interest. Companies building large-scale protein language models, cellular response prediction engines, and multi-modal patient digital twins collectively raised $1.8 billion in 2025. These platforms increasingly serve as the infrastructure layer upon which therapeutic programs are built, creating a “picks and shovels” thesis within AI-enabled drug discovery that attracted technology-focused investors like a16z Bio, Google Ventures, and Microsoft's M12 alongside traditional life sciences funds.
The life sciences exit environment improved meaningfully in 2025, though it remains well below the frenzied pace of 2020–2021. A total of 42 life sciences companies completed IPOs on U.S. exchanges, raising $8.1 billion in aggregate—up from just 28 IPOs and $4.9 billion in 2024. The median post-IPO market capitalization was $620 million, and notably, 71% of the 2025 IPO class traded above their offering price at year-end, a sharp improvement from the 48% figure in 2024. Several standout debuts captured market attention and renewed institutional appetite for life sciences public offerings.
On the M&A front, life sciences acquisitions reached $142 billion in total disclosed value across 186 transactions. Large pharma remained the primary acquirer, with the top ten deals accounting for $78 billion. The median acquisition premium for public targets was 62%, reflecting competitive dynamics among acquirers facing patent cliffs and thin late-stage pipelines. Importantly, early-stage acquisitions—deals for companies at or before Phase II—rose to 34% of all transactions by count, up from 26% in 2024, suggesting that large pharma is increasingly willing to pay for clinical-stage de-risking rather than waiting for Phase III data.
The United States maintained its position as the dominant life sciences venture market, capturing $24.1 billion or 62.8% of global investment. Boston/Cambridge remained the undisputed epicenter, attracting $8.4 billion—more than any single country outside the U.S. San Francisco and the broader Bay Area accounted for $5.2 billion, while the New York/New Jersey corridor continued its emergence as a third major hub with $2.1 billion. Importantly, secondary hubs showed accelerating momentum: the Research Triangle in North Carolina drew $1.4 billion (up 45% YoY), and Houston's Texas Medical Center ecosystem attracted $890 million.
Europe's life sciences venture market reached $7.8 billion, a 19% increase over 2024 and a new record for the region. The United Kingdom led with $3.1 billion, buoyed by the Oxford/Cambridge cluster's growing maturity and favorable regulatory pathways through the MHRA's Innovation Passport program. Germany ($1.6B), Switzerland ($1.2B), and France ($980M) rounded out the top four. The European Investment Fund's expanded mandate for life sciences venture contributed an estimated $1.1 billion in new LP commitments to European healthcare funds.
Asia-Pacific life sciences venture investment totaled $5.8 billion. China, despite continued geopolitical headwinds and the BIOSECURE Act's impact on cross-border collaborations, remained the largest market at $3.2 billion, though this represented a 12% decline from 2024. Chinese life sciences venture increasingly focused on domestic opportunities and differentiated assets for global out-licensing. Japan ($1.1B) emerged as a notable bright spot, with government-backed initiatives to stimulate biotech entrepreneurship showing tangible results for the first time. South Korea ($680M) and Australia ($440M) also posted record years.
The composition of life sciences founding teams continued to evolve in 2025, though progress on representation remained uneven. Women-led life sciences startups received $4.2 billion in venture funding, representing 10.9% of total capital—up from 9.3% in 2024 but still dramatically below parity. At the seed stage specifically, the picture was somewhat brighter: women founders received 16.4% of seed-stage capital, reflecting the impact of emerging funds with explicit mandates to invest in diverse founding teams. Companies founded by underrepresented minorities received 4.8% of total life sciences VC, up from 3.9% in 2024.
Academic spinouts accounted for 38% of newly formed life sciences companies in 2025, a slight increase from 35% in 2024. The top institutional sources of venture-backed spinouts were MIT, Stanford, Harvard, UCSF, and the Broad Institute. Notably, the average age of first-time life sciences founders fell to 34, down from 37 in 2020, suggesting that the ecosystem is encouraging earlier entrepreneurial risk-taking. The rise of venture creation studios and entrepreneur-in-residence programs at major research institutions contributed to this trend.
“The next generation of life sciences companies will be built by founders who are as fluent in machine learning as they are in molecular biology. The investors who can identify and support those hybrid teams earliest will capture disproportionate value.”
Life sciences-focused venture funds raised $19.2 billion in new commitments during 2025, a 15% increase over 2024 and a signal of renewed LP confidence in the asset class. The fundraising environment was bifurcated: established franchises with strong track records closed quickly, often oversubscribed, while emerging managers faced longer timelines but found receptive audiences among family offices, endowments, and strategically motivated corporate LPs. A total of 62 new life sciences venture funds held final closes in 2025, including 18 debut funds.
The emergence of specialized micro-funds targeting specific niches—AI-bio platforms, rare disease, diagnostics, and early-stage therapeutics—was a defining trend. These sub-$100 million vehicles, often led by former operators or physician-scientists with deep domain expertise, filled a critical gap in the ecosystem by providing patient capital and hands-on support at stages too early for traditional institutional healthcare funds. This structural evolution mirrors what occurred in enterprise software venture capital a decade ago and signals a maturing, increasingly stratified life sciences venture market.
As we look ahead to 2026, several forces will shape the trajectory of life sciences venture capital. We identify the following as the most consequential dynamics to monitor:
We anticipate total life sciences venture investment in 2026 will reach $42–45 billion, representing 10–17% growth over 2025. The early-stage segment, where Legacy Venture Capital operates, is poised for particular strength: the combination of declining discovery costs through AI, a rich pipeline of academic innovation, and expanding exit pathways for early-stage companies creates a compelling environment for pre-seed and seed investment in the year ahead.
This report draws on data from PitchBook, Crunchbase, BioCentury, Evaluate Pharma, and proprietary Legacy Venture Capital deal tracking across more than 3,200 life sciences transactions globally. All figures represent calendar year 2025 (January 1 through December 31) unless otherwise noted. Sector classifications follow the Legacy Venture Capital taxonomy, which may differ from other industry sources.
The 2025 landscape tells a story of disciplined recovery. Capital returned to life sciences venture not with the euphoric abandon of 2021 but with the rigor and intentionality that a complex, high-stakes asset class demands. For founders building companies at the intersection of deep science and transformative technology, the opportunity set has never been richer. For investors willing to underwrite technical risk with conviction and expertise, the rewards have never been more clearly defined. At Legacy Venture Capital, we remain committed to deploying capital at the earliest stages of life sciences innovation—where the science is hardest, the founders are boldest, and the impact is most profound.
Explore how Legacy Venture Capital is positioned within this evolving landscape.
View Our Portfolio